Brolucizumab 6mg

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Macular Polypoidal Choroidal Vasculopathy (PCV)Neovascular Age-Related Macular Degeneration

Phase 3

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

CompletedNCT04047472

Novartis PharmaceuticalsNeovascular Age-Related Macular Degeneration

Start: 2019-11-29End: 2024-02-28Updated: 2024-12-09

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

CompletedNCT05666804

Novartis PharmaceuticalsMacular Polypoidal Choroidal Vasculopathy (PCV)

Start: 2023-02-06End: 2025-09-10Updated: 2025-12-15